Clinical Trial Update: Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD) [Phase 2]

View source ↗

Summary

Phase 2 open-label SWAD trial evaluated switching virologically suppressed HIV-1 adults from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Abacavir/Lamivudine/Dolutegravir (abacavir/lamivudine/dolutegravir)
• Dolutegravir (dolutegravir)
• NEVIRAPINE (nevirapine)
• abacavir/lamivudine (abacavir/lamivudine)

Snippet

Sponsor: Nantes University Hospital | Conditions: HIV-1 Infection | Phase 2 | Status: COMPLETED